MCL1 and acute myeloid leukemia: Together, these findings raise the possibility that alterations in the activation status of VEGF-related pathways as well as kinases e.g., MAPK9, FER and MAPKAPK5 may contribute to the anti-AML activity of combined Src/MCL-1 inhibitor exposure.